Literature DB >> 7576422

Profiles of neuromuscular diseases. Spinal muscular atrophy.

G T Carter1, R T Abresch, W M Fowler, E R Johnson, D D Kilmer, C M McDonald.   

Abstract

Forty-five individuals with spinal muscular atrophy (SMA) types II and III were evaluated prospectively over a 10-yr period to develop an impairment and disability profile. SMA II subjects showed marked weakness and progressive decline of strength. Mean manual muscle test (MMT) score for all muscles combined was 2.3 +/- 0.6, with a decline in strength of -0.24 MMT units per decade. SMA III individuals had a relatively static or very slowly progressive course and were far stronger. Mean MMT score for all muscles combined was 3.8 +/- 0.7, and the decline in strength per decade was not significant. In both types proximal weakness was greater than distal, but there was greater involvement of the lower extremities and the extensor muscle groups only in SMA II. Contractures, progressive scoliosis, and restrictive lung disease (RLD) were present in most of the SMA II individuals, but these complications were rare in SMA III. Maximal expiratory pressures were affected earlier and to a greater degree than vital capacity. Seventy-eight percent of those with SMA II had scoliosis with a mean Cobb angle of the primary curve of 62 +/- 37 degrees. Forty-one percent had severe RLD, and 17% had moderate RLD. In both types, 63% had abnormal electrocardiograms although most had minor findings. Timed motor performance and functional evaluations indicated that muscle weakness translated to substantial disability in both SMA II and III, with more severe impairment noted in SMA II. Neither type was associated with abnormal means scores on intellectual and neuropsychologic test batteries.

Entities:  

Mesh:

Year:  1995        PMID: 7576422     DOI: 10.1097/00002060-199509001-00009

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  20 in total

1.  [Current strategies of conservative and operative treatment of the most frequent muscular disorders].

Authors:  A Fujak; R Forst; J Forst
Journal:  Orthopade       Date:  2010-01       Impact factor: 1.087

Review 2.  Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases.

Authors:  Craig M McDonald
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

Review 3.  Prevention and management of limb contractures in neuromuscular diseases.

Authors:  Andrew J Skalsky; Craig M McDonald
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

4.  Functional performance and muscle strength phenotypes in men and women with Danon disease.

Authors:  Jennifer E Stevens-Lapsley; Laurel R Kramer; Jaclyn E Balter; Jean Jirikowic; Dana Boucek; Matthew Taylor
Journal:  Muscle Nerve       Date:  2010-12       Impact factor: 3.217

5.  Muscle study in experimental scoliosis in rabbits with costotransversectomy: evidence of ischemic process.

Authors:  Lineu C Werneck; Vlademir A Cousseau; Xavier S Graells; Mauricio C Werneck; Rosana H Scola
Journal:  Eur Spine J       Date:  2008-01-22       Impact factor: 3.134

6.  Pain in youths with neuromuscular disease.

Authors:  Joyce M Engel; Deborah Kartin; Gregory T Carter; Mark P Jensen; Kenneth M Jaffe
Journal:  Am J Hosp Palliat Care       Date:  2009 Oct-Nov       Impact factor: 2.500

Review 7.  Bone health and associated metabolic complications in neuromuscular diseases.

Authors:  Nanette C Joyce; Lauren P Hache; Paula R Clemens
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-10-17       Impact factor: 1.784

8.  Growth and muscle defects in mice lacking adult myosin heavy chain genes.

Authors:  L J Acakpo-Satchivi; W Edelmann; C Sartorius; B D Lu; P A Wahr; S C Watkins; J M Metzger; L Leinwand; R Kucherlapati
Journal:  J Cell Biol       Date:  1997-12-01       Impact factor: 10.539

9.  Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial.

Authors:  Andreea Mihaela Seferian; Amélie Moraux; Aurélie Canal; Valérie Decostre; Oumar Diebate; Anne Gaëlle Le Moing; Teresa Gidaro; Nicolas Deconinck; Frauke Van Parys; Wendy Vereecke; Sylvia Wittevrongel; Mélanie Annoussamy; Michèle Mayer; Kim Maincent; Jean-Marie Cuisset; Vincent Tiffreau; Severine Denis; Virginie Jousten; Susana Quijano-Roy; Thomas Voit; Jean-Yves Hogrel; Laurent Servais
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

10.  Cervical Spinal Cord Atrophy Profile in Adult SMN1-Linked SMA.

Authors:  Mohamed-Mounir El Mendili; Timothée Lenglet; Tanya Stojkovic; Anthony Behin; Raquel Guimarães-Costa; François Salachas; Vincent Meininger; Gaelle Bruneteau; Nadine Le Forestier; Pascal Laforêt; Stéphane Lehéricy; Habib Benali; Pierre-François Pradat
Journal:  PLoS One       Date:  2016-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.